DK0896822T3 - 4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister - Google Patents

4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister

Info

Publication number: DK0896822T3
Authority: DK; Denmark
Prior art keywords: neuropeptide; aminopyrrole; pyrimidines; receptor antagonists; medicament
Prior art date: 1997-08-05

Application number

DK98305963T

Other languages

English (en)

Inventor

Robert Lee Dow

Bonnie Frances Tate

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-05

Filing date

1998-07-27

Publication date

2003-06-02

1998-07-27 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-06-02 Application granted granted Critical

2003-06-02 Publication of DK0896822T3 publication Critical patent/DK0896822T3/da

Links

WAUGGYPDCQZJKK-UHFFFAOYSA-N 1h-pyrrol-3-amine Chemical compound NC=1C=CNC=1 WAUGGYPDCQZJKK-UHFFFAOYSA-N 0.000 title 1
239000002660 neuropeptide Y receptor antagonist Substances 0.000 title 1
150000003230 pyrimidines Chemical class 0.000 title 1
101710151321 Melanostatin Proteins 0.000 abstract 1
102400000064 Neuropeptide Y Human genes 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK98305963T 1997-08-05 1998-07-27 4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister DK0896822T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US5530797P	1997-08-05	1997-08-05

Publications (1)

Publication Number	Publication Date
DK0896822T3 true DK0896822T3 (da)	2003-06-02

Family

ID=21997003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98305963T DK0896822T3 (da)	1997-08-05	1998-07-27	4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister

Country Status (16)

Country	Link
US (1)	US6040310A (da)
EP (1)	EP0896822B1 (da)
JP (1)	JP2978898B2 (da)
KR (1)	KR19990023355A (da)
AT (1)	ATE234098T1 (da)
AU (1)	AU726676B2 (da)
CA (1)	CA2244621C (da)
DE (1)	DE69812010T2 (da)
DK (1)	DK0896822T3 (da)
ES (1)	ES2191908T3 (da)
HU (1)	HUP9801792A3 (da)
IL (1)	IL125591A0 (da)
NZ (1)	NZ331233A (da)
PT (1)	PT896822E (da)
TW (1)	TW434015B (da)
ZA (1)	ZA986971B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050070499A1 (en) *	1999-11-08	2005-03-31	Pfizer Inc.	Compounds for the treatment of female sexual dysfunction
US20020091129A1 (en) *	2000-11-20	2002-07-11	Mitradev Boolell	Treatment of premature ejaculation
JP2005506042A (ja)	2000-12-12	2005-03-03	ユニヴァーシティーオブコネティカット	細胞トランスポーターをコードするポリヌクレオチド、およびその使用方法
US20030082647A1 (en) *	2000-12-12	2003-05-01	Reenan Robert A.	Transporter protein
US8377906B2 (en)	2004-06-04	2013-02-19	Ethicon, Inc.	Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
US8129359B2 (en)	2004-06-04	2012-03-06	Ethicon, Inc.	Composition and method for treating post-surgical pain
WO2006108218A1 (en) *	2005-04-15	2006-10-19	Regenertech Pty Limited	Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration
CN106188060A (zh) *	2015-04-29	2016-12-07	厦门大学	嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
KR102048719B1 (ko)	2015-08-13	2019-11-26	베이징 한미 파마슈티컬 컴퍼니 리미티드	Irak4억제제 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE147386T1 (de) *	1991-08-12	1997-01-15	Takeda Chemical Industries Ltd	Kondensierte pyrimidinderivate, ihre herstellung und ihre verwendung als antitumormittel
US6562862B1 (en) *	1994-10-20	2003-05-13	Eli Lilly And Company	Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
WO1996014307A1 (en) *	1994-11-07	1996-05-17	Pfizer Inc.	Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
US5602024A (en) *	1994-12-02	1997-02-11	Synaptic Pharmaceutical Corporation	DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
EP0729758A3 (en) *	1995-03-02	1997-10-29	Pfizer	Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
EP0759441A3 (en) *	1995-06-30	1999-06-30	Eli Lilly And Company	Methods of treating neuropeptide Y-associated conditions

1998
- 1998-07-27 AT AT98305963T patent/ATE234098T1/de not_active IP Right Cessation
- 1998-07-27 DK DK98305963T patent/DK0896822T3/da active
- 1998-07-27 ES ES98305963T patent/ES2191908T3/es not_active Expired - Lifetime
- 1998-07-27 PT PT98305963T patent/PT896822E/pt unknown
- 1998-07-27 EP EP98305963A patent/EP0896822B1/en not_active Expired - Lifetime
- 1998-07-27 DE DE69812010T patent/DE69812010T2/de not_active Expired - Fee Related
- 1998-07-29 US US09/124,025 patent/US6040310A/en not_active Expired - Fee Related
- 1998-07-30 IL IL12559198A patent/IL125591A0/xx unknown
- 1998-07-31 CA CA002244621A patent/CA2244621C/en not_active Expired - Fee Related
- 1998-07-31 TW TW087112649A patent/TW434015B/zh active
- 1998-08-03 AU AU78694/98A patent/AU726676B2/en not_active Ceased
- 1998-08-03 NZ NZ331233A patent/NZ331233A/xx unknown
- 1998-08-04 KR KR1019980031728A patent/KR19990023355A/ko not_active Ceased
- 1998-08-04 ZA ZA9806971A patent/ZA986971B/xx unknown
- 1998-08-04 JP JP10220638A patent/JP2978898B2/ja not_active Expired - Fee Related
- 1998-08-04 HU HU9801792A patent/HUP9801792A3/hu unknown

Also Published As

Publication number	Publication date
HU9801792D0 (en)	1998-09-28
ZA986971B (en)	2000-02-04
JPH11130774A (ja)	1999-05-18
HUP9801792A2 (hu)	2000-02-28
NZ331233A (en)	2000-09-29
DE69812010T2 (de)	2004-02-26
JP2978898B2 (ja)	1999-11-15
EP0896822B1 (en)	2003-03-12
AU726676B2 (en)	2000-11-16
DE69812010D1 (de)	2003-04-17
IL125591A0 (en)	1999-03-12
EP0896822A1 (en)	1999-02-17
ES2191908T3 (es)	2003-09-16
TW434015B (en)	2001-05-16
CA2244621C (en)	2003-07-29
ATE234098T1 (de)	2003-03-15
CA2244621A1 (en)	1999-02-05
PT896822E (pt)	2003-07-31
US6040310A (en)	2000-03-21
HUP9801792A3 (en)	2001-04-28
KR19990023355A (ko)	1999-03-25
AU7869498A (en)	1999-02-18

Publication	Publication Date	Title
ATE324371T1 (de)	2006-05-15	N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
TR200200579T2 (tr)	2002-12-23	Amino-tirazolpiridin türevleri.
IS6362A (is)	2002-04-26	Úrea (eða þvagefnis) efnasambönd sem hafa múskarín viðtaka mótlyfs virkni
DE69034103D1 (de)	2003-10-30	Imidazoalkensäure
EA200300717A1 (ru)	2003-12-25	Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
DK0386675T3 (da)	1996-06-24	Xanthinderivater
SE9904508D0 (sv)	1999-12-09	New compounds
NO20020574L (no)	2002-03-25	Substituerte 1,5-dihydropyrrol-2-on derivater som er virksomme som NMDA-reseptorantagonister for behandlingen avsmertetilstanden
SI1578741T1 (sl)	2011-11-30	Aromatske spojine kot protivnetna imunomodulatorna in antiproliferativna sredstva
DK0733051T3 (da)	2000-04-03	Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister
DK0896822T3 (da)	2003-06-02	4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister
ATE301642T1 (de)	2005-08-15	Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
DK0902018T3 (da)	2008-10-20	2-(arylpheny)amino-imidazolinderivater
AU2002245005A1 (en)	2002-10-08	Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
DE60121048D1 (de)	2006-08-03	PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
WO2004048381A3 (en)	2004-08-05	Pyrazoloazepine compounds as pharmaceutical agents
SE0102058D0 (sv)	2001-06-08	New Salts II
DE69627519D1 (de)	2003-05-22	Sesquiterpen-derivate mit antiviraler aktivität
CA2445620A1 (en)	2002-12-12	Tetracyclic compounds as pde5-inhibitors
ATE285759T1 (de)	2005-01-15	Neuropeptid y antagonisten
ATE319452T1 (de)	2006-03-15	Arzneimittel gegen essstörungen
ATE338046T1 (de)	2006-09-15	2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza- cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität
ATE242227T1 (de)	2003-06-15	Tetrahydrofuranderivate